Dr. Sartor on Sipuleucel-T in mCRPC

Oliver Sartor, MD
Published: Tuesday, May 23, 2017


  Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American–treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.
 

  Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American–treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x